de Geode Capital Management PTC Therapeutics PTCT Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 180 M | Vender |
2,207,376
-2,578
| -0.1% | -USD 186 k | 0.01% | 862 |
|
|
2026
Q1 | USD 151 M | Comprar |
2,209,954
+193,892
| +10% | +USD 13.7 M | 0.01% | 853 |
|
|
2025
Q4 | USD 153 M | Comprar |
2,016,062
+65,184
| +3% | +USD 4.74 M | 0.01% | 834 |
|
|
2025
Q3 | USD 120 M | Comprar |
1,950,878
+16,285
| +0.8% | +USD 848 k | 0.01% | 960 |
|
|
2025
Q2 | USD 94.5 M | Comprar |
1,934,593
+60,707
| +3% | +USD 2.88 M | 0.01% | 1063 |
|
|
2025
Q1 | USD 95.5 M | Comprar |
1,873,886
+76,870
| +4% | +USD 3.84 M | 0.01% | 996 |
|
|
2024
Q4 | USD 81.1 M | Vender |
1,797,016
-1,650
| -0.1% | -USD 70.6 k | 0.01% | 1126 |
|
|
2024
Q3 | USD 66.7 M | Comprar |
1,798,666
+10,886
| +0.6% | +USD 364 k | 0.01% | 1252 |
|
|
2024
Q2 | USD 54.7 M | Comprar |
1,787,780
+124,712
| +7% | +USD 4.04 M | ﹤0.01% | 1295 |
|
|
2024
Q1 | USD 48.4 M | Comprar |
1,663,068
+51,843
| +3% | +USD 1.45 M | ﹤0.01% | 1378 |
|
|
2023
Q4 | USD 44.4 M | Comprar |
1,611,225
+89,396
| +6% | +USD 2.04 M | ﹤0.01% | 1417 |
|
|
2023
Q3 | USD 34.1 M | Comprar |
1,521,829
+62,289
| +4% | +USD 2.32 M | ﹤0.01% | 1490 |
|
|
2023
Q2 | USD 59.4 M | Comprar |
1,459,540
+74,130
| +5% | +USD 3.63 M | 0.01% | 1123 |
|
|
2023
Q1 | USD 67.1 M | Comprar |
1,385,410
+58,786
| +4% | +USD 2.69 M | 0.01% | 987 |
|
|
2022
Q4 | USD 50.6 M | Comprar |
1,326,624
+47,426
| +4% | +USD 1.97 M | 0.01% | 1137 |
|
|
2022
Q3 | USD 64.2 M | Vender |
1,279,198
-54,321
| -4% | -USD 2.66 M | 0.01% | 918 |
|
|
2022
Q2 | USD 53.4 M | Comprar |
1,333,519
+42,380
| +3% | +USD 1.49 M | 0.01% | 1067 |
|
|
2022
Q1 | USD 48.2 M | Comprar |
1,291,139
+19,009
| +1% | +USD 732 k | 0.01% | 1277 |
|
|
2021
Q4 | USD 50.7 M | Vender |
1,272,130
-6,496
| -0.5% | -USD 249 k | 0.01% | 1305 |
|
|
2021
Q3 | USD 47.6 M | Comprar |
1,278,626
+11,287
| +0.9% | +USD 464 k | 0.01% | 1321 |
|
|
2021
Q2 | USD 53.6 M | Comprar |
1,267,339
+118,239
| +10% | +USD 5.07 M | 0.01% | 1248 |
|
|
2021
Q1 | USD 54.4 M | Comprar |
1,149,100
+104,952
| +10% | +USD 6.23 M | 0.01% | 1162 |
|
|
2020
Q4 | USD 63.7 M | Comprar |
1,044,148
+64,473
| +7% | +USD 3.8 M | 0.01% | 948 |
|
|
2020
Q3 | USD 45.8 M | Comprar |
979,675
+18,444
| +2% | +USD 908 k | 0.01% | 968 |
|
|
2020
Q2 | USD 48.8 M | Comprar |
961,231
+33,785
| +4% | +USD 1.66 M | 0.01% | 906 |
|
|
2020
Q1 | USD 41.4 M | Comprar |
927,446
+67,097
| +8% | +USD 3.38 M | 0.01% | 861 |
|
|
2019
Q4 | USD 41.3 M | Comprar |
860,349
+73,080
| +9% | +USD 3.11 M | 0.01% | 1062 |
|
|
2019
Q3 | USD 26.6 M | Comprar |
787,269
+52,852
| +7% | +USD 2.3 M | 0.01% | 1287 |
|
|
2019
Q2 | USD 33 M | Comprar |
734,417
+53,069
| +8% | +USD 2.1 M | 0.01% | 1136 |
|
|
2019
Q1 | USD 25.6 M | Comprar |
681,348
+117,942
| +21% | +USD 3.96 M | 0.01% | 1252 |
|
|
2018
Q4 | USD 19.3 M | Comprar |
563,406
+37,593
| +7% | +USD 1.35 M | 0.01% | 1305 |
|
|
2018
Q3 | USD 24.7 M | Comprar |
525,813
+79,294
| +18% | +USD 3.28 M | 0.01% | 1251 |
|
|
2018
Q2 | USD 15.1 M | Comprar |
446,519
+81,197
| +22% | +USD 2.53 M | ﹤0.01% | 1564 |
|
|
2018
Q1 | USD 9.9 M | Comprar |
365,322
+50,210
| +16% | +USD 1.27 M | ﹤0.01% | 1771 |
|
|
2017
Q4 | USD 5.26 M | Vender |
315,112
-47,893
| -13% | -USD 811 k | ﹤0.01% | 2182 |
|
|
2017
Q3 | USD 7.26 M | Comprar |
363,005
+71,590
| +25% | +USD 1.4 M | ﹤0.01% | 1968 |
|
|
2017
Q2 | USD 5.34 M | Comprar |
291,415
+21,151
| +8% | +USD 285 k | ﹤0.01% | 2105 |
|
|
2017
Q1 | USD 2.66 M | Comprar |
270,264
+10,958
| +4% | +USD 133 k | ﹤0.01% | 2494 |
|
|
2016
Q4 | USD 2.83 M | Comprar |
259,306
+30,111
| +13% | +USD 316 k | ﹤0.01% | 2425 |
|
|
2016
Q3 | USD 3.21 M | Comprar |
229,195
+3,442
| +2% | +USD 28 k | ﹤0.01% | 2254 |
|
|
2016
Q2 | USD 1.58 M | Comprar |
225,753
+1,700
| +0.8% | +USD 12.5 k | ﹤0.01% | 2640 |
|
|
2016
Q1 | USD 1.44 M | Comprar |
224,053
+5,167
| +2% | +USD 89.7 k | ﹤0.01% | 2670 |
|
|
2015
Q4 | USD 7.09 M | Comprar |
218,886
+4,743
| +2% | +USD 140 k | ﹤0.01% | 1616 |
|
|
2015
Q3 | USD 5.72 M | Comprar |
214,143
+55,661
| +35% | +USD 2.38 M | ﹤0.01% | 1757 |
|
|
2015
Q2 | USD 7.63 M | Comprar |
158,482
+13,379
| +9% | +USD 781 k | ﹤0.01% | 1609 |
|
|
2015
Q1 | USD 8.83 M | Vender |
145,103
-985
| -0.7% | -USD 60.1 k | 0.01% | 1477 |
|
|
2014
Q4 | USD 7.56 M | Comprar |
146,088
+16,134
| +12% | +USD 710 k | ﹤0.01% | 1554 |
|
|
2014
Q3 | USD 5.72 M | Comprar |
129,954
+2,122
| +2% | +USD 66.4 k | ﹤0.01% | 1679 |
|
|
2014
Q2 | USD 3.34 M | Comprar |
127,832
+27,938
| +28% | +USD 598 k | ﹤0.01% | 2051 |
|
|
2014
Q1 | USD 2.61 M | Comprar |
99,894
+50,799
| +103% | +USD 1.37 M | ﹤0.01% | 2180 |
|
|
2013
Q4 | USD 833 k | Comprar |
49,095
+693
| +1% | +USD 12.2 k | ﹤0.01% | 2829 |
|
|
2013
Q3 | USD 1.04 M | Comprar |
+48,402
| Nuevas | +USD 841 k | ﹤0.01% | 2567 |
|
Otros fondos que tienen PTCT en su cartera
Posición de Geode Capital Management en PTCT: resumen de T2 2026
Geode Capital Management redujo su participación en PTC Therapeutics (PTCT) en 0.12% durante T2 2026, al vender acciones por un valor estimado de USD 186 k, y conservó 2,207,376 acciones valuadas en USD 180 M. La posición representa 0.01% de la cartera y ocupa el puesto #862.
Geode Capital Management reportó por primera vez una posición en PTCT en T3 2013 y la ha mantenido durante 52 trimestres desde entonces. Al cierre de T2 2026, 384 fondos que sigue Wall St. Rank mantienen una posición en PTCT.
- Al cierre de T2 2026, Geode Capital Management tenía 2,207,376 acciones de PTC Therapeutics con un valor de USD 180 M.
- Geode Capital Management vendió 2,578 acciones de PTC Therapeutics en T2 2026, por un valor estimado de USD 186 k.
- PTC Therapeutics representó 0.01% de la cartera de Geode Capital Management en T2 2026 y fue su posición número 862.
- Geode Capital Management reportó por primera vez una posición en PTC Therapeutics en T3 2013 y la ha mantenido durante 52 trimestres desde entonces.
- Al cierre de T2 2026, 384 fondos que sigue Wall St. Rank tenían PTC Therapeutics en cartera.
Según el Informe 13F de Geode Capital Management correspondiente a T2 2026, presentado el 12 ago 2026.